Congruently, exploration of scRNA-seq data (via Single Cell Portal) revealed that elevated levels of ITGAV, ITGB3 and ITGB5 in myeloid cells are negative predictors of ICI therapy response in melanoma and renal cell carcinoma patients (Fig. 6I). The gene discussed is ITGB3; the disease is hereditary clear cell renal cell carcinoma.